These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29233768)

  • 1. Vaccine development targeting lipopolysaccharide structure modification.
    Zhao Y; Arce-Gorvel V; Conde-Álvarez R; Moriyon I; Gorvel JP
    Microbes Infect; 2018; 20(9-10):455-460. PubMed ID: 29233768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical structure, molecular conformation, and bioactivity of endotoxins.
    Seydel U; Schromm AB; Blunck R; Brandenburg K
    Chem Immunol; 2000; 74():5-24. PubMed ID: 10608079
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipopolysaccharide: a tool and target in enterobacterial vaccine development.
    Nagy G; Pál T
    Biol Chem; 2008 May; 389(5):513-20. PubMed ID: 18953717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of endotoxin and its impact on pathogenesis.
    Trent MS; Stead CM; Tran AX; Hankins JV
    J Endotoxin Res; 2006; 12(4):205-23. PubMed ID: 16953973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inductions of TNF-alpha and IGTP, IIGP by structurally diverse classic and non-classic lipopolysaccharides.
    Lapaque N; Takeuchi O; Corrales F; Akira S; Moriyon I; Howard JC; Gorvel JP
    Cell Microbiol; 2006 Mar; 8(3):401-13. PubMed ID: 16469053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipopolysaccharide as a target for brucellosis vaccine design.
    Conde-Álvarez R; Arce-Gorvel V; Gil-Ramírez Y; Iriarte M; Grilló MJ; Gorvel JP; Moriyón I
    Microb Pathog; 2013 May; 58():29-34. PubMed ID: 23219811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O-aminoacylation of bacterial glycoconjugates: from native structure to vaccine design.
    Gamian A; Mieszała M; Lipiński T; Zielińska-Kuźniarz K; Gawlik-Jędrysiak M; Dzierzba K; Pietkiewicz J; Szeja W
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1781-91. PubMed ID: 21902628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective efficacy afforded by live Pasteurella multocida vaccines in chickens is independent of lipopolysaccharide outer core structure.
    Harper M; John M; Edmunds M; Wright A; Ford M; Turni C; Blackall PJ; Cox A; Adler B; Boyce JD
    Vaccine; 2016 Mar; 34(14):1696-703. PubMed ID: 26892738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Generation of vaccine strains of gram-negative bacteria with reduced adverse reactions].
    Dentovskaia SV; Shaĭhutdinov RZ; Knirel' IuA; Ivanov SA; Anisimov AP
    Mol Gen Mikrobiol Virusol; 2006; (2):3-8. PubMed ID: 16755996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aspects of Vibrio cholerae lipopolysaccharide].
    Lobanov VV; Sukhar' VV
    Zh Mikrobiol Epidemiol Immunobiol; 2002; (2):102-7. PubMed ID: 12043141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria.
    Yethon JA; Whitfield C
    Curr Drug Targets Infect Disord; 2001 Aug; 1(2):91-106. PubMed ID: 12455407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R-form lipopolysaccharides (LPS) of Gram-negative bacteria as possible vaccine antigens.
    Stanislavsky ES; Makarenko TA; Kholodkova EV; Lugowski C
    FEMS Immunol Med Microbiol; 1997 Jul; 18(3):139-45. PubMed ID: 9271164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nontoxic, idiotope vaccine against gram-negative bacterial infections.
    Su S; Ward MM; Apicella MA; Ward RE
    J Immunol; 1992 Jan; 148(1):234-8. PubMed ID: 1727868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].
    Rietschel ET; Brade H
    Infection; 1987; 15(2):133-41. PubMed ID: 2439461
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipopolysaccharide heterogeneity: innate host responses to bacterial modification of lipid a structure.
    Dixon DR; Darveau RP
    J Dent Res; 2005 Jul; 84(7):584-95. PubMed ID: 15972584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second generation meningococcal OMP-LPS vaccines.
    Poolman JT; van der Ley PA; Wiertz EJ; Hoogerhout P
    NIPH Ann; 1991 Dec; 14(2):233-41. PubMed ID: 1725922
    [No Abstract]   [Full Text] [Related]  

  • 18. Diversity of lipopolysaccharide structures in Campylobacter jejuni.
    Penner JL; Aspinall GO
    J Infect Dis; 1997 Dec; 176 Suppl 2():S135-8. PubMed ID: 9396697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice.
    Román BS; Garrido V; Muñoz PM; Arribillaga L; García B; De Andrés X; Zabaleta V; Mansilla C; Farrán I; Lasa I; De Andrés D; Amorena B; Lasarte JJ; Grilló MJ
    Vet Res; 2012 Apr; 43(1):31. PubMed ID: 22515195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].
    Rietschel ET; Brade H
    Infection; 1987; 15 Suppl 2():S76-84. PubMed ID: 2440812
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.